Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Otitis Media Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Otitis Media Overview | 9 | 1 |
| Pipeline Products for Otitis Media Comparative Analysis | 10 | 1 |
| Otitis Media Therapeutics under Development by Companies | 11 | 1 |
| Otitis Media Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Otitis Media Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Otitis Media Products under Development by Companies | 16 | 1 |
| Otitis Media Products under Investigation by Universities/Institutes | 17 | 1 |
| Otitis Media Companies Involved in Therapeutics Development | 18 | 10 |
| Cellceutix Corporation | 18 | 1 |
| ContraFect Corporation | 19 | 1 |
| GlaxoSmithKline Plc | 20 | 1 |
| Lee's Pharmaceutical Holdings Limited | 21 | 1 |
| Madam Therapeutics B.V. | 22 | 1 |
| Merck &Co., Inc. | 23 | 1 |
| MerLion Pharmaceuticals Pte Ltd | 24 | 1 |
| Oticpharma Ltd | 25 | 1 |
| Otonomy, Inc. | 26 | 1 |
| Yuhan Corporation | 27 | 1 |
| Otitis Media Therapeutics Assessment | 28 | 10 |
| Assessment by Monotherapy Products | 28 | 1 |
| Assessment by Combination Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 38 |
| (dexamethasone acetate + piperacillin sodium + tazobactam sodium) Drug Profile | 38 | 1 |
| betahistine dihydrochloride Drug Profile | 39 | 1 |
| brilacidin tetrahydrochloride Drug Profile | 40 | 9 |
| CF-303 Drug Profile | 49 | 1 |
| CF-309 Drug Profile | 50 | 1 |
| ciprofloxacin hydrochloride Drug Profile | 51 | 4 |
| ciprofloxacin hydrochloride SR Drug Profile | 55 | 1 |
| finafloxacin Drug Profile | 56 | 3 |
| GSK-2189242A Drug Profile | 59 | 1 |
| pazufloxacin Drug Profile | 60 | 1 |
| PCL-1402 Drug Profile | 61 | 1 |
| Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections Drug Profile | 62 | 1 |
| Small Molecules for Otitis Media Drug Profile | 63 | 1 |
| solithromycin Drug Profile | 64 | 12 |
| Otitis Media Dormant Projects | 76 | 1 |
| Otitis Media Product Development Milestones | 77 | 8 |
| Featured News &Press Releases | 77 | 1 |
| May 20, 2016: Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO | 77 | 1 |
| May 16, 2016: Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings | 77 | 1 |
| Mar 18, 2016: Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology | 78 | 1 |
| Mar 03, 2016: Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes | 78 | 1 |
| Mar 02, 2016: Otonomy Announces Commercial Availability of OTIPRIO | 79 | 1 |
| Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery | 79 | 1 |
| Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes | 80 | 1 |
| Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting | 80 | 1 |
| May 07, 2015: Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes | 81 | 1 |
| Apr 28, 2015: Otonomy Announces FDA Acceptance of AuriPro New Drug Application | 81 | 1 |
| Apr 27, 2015: Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference | 82 | 1 |
| Apr 21, 2015: Otonomy to Present AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference | 82 | 1 |
| Mar 26, 2015: Otonomy Initiates Phase 2 Clinical Trial for AuriPro in Label Expansion Indication | 83 | 1 |
| Feb 26, 2015: Otonomy Submits New Drug Application to the FDA for AuriPro | 83 | 1 |
| Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery | 84 | 1 |
| Appendix | 85 | 2 |
| Methodology | 85 | 1 |
| Coverage | 85 | 1 |
| Secondary Research | 85 | 1 |
| Primary Research | 85 | 1 |
| Expert Panel Validation | 85 | 1 |
| Contact Us | 85 | 1 |
| Disclaimer | 86 | 1 |